<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641537</url>
  </required_header>
  <id_info>
    <org_study_id>27820</org_study_id>
    <secondary_id>2007-000381-20</secondary_id>
    <nct_id>NCT00641537</nct_id>
  </id_info>
  <brief_title>CLARITY Extension Study</brief_title>
  <official_title>A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of this extension trial was to further evaluate the safety and tolerability of&#xD;
      oral cladribine in subjects who have previously completed treatment within Trial 25643&#xD;
      (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2008</start_date>
  <completion_date type="Actual">December 31, 2011</completion_date>
  <primary_completion_date type="Actual">December 31, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120</measure>
    <time_frame>Baseline, Week 120</time_frame>
    <description>Mean change from baseline in absolute lymphocyte count, platelet, neutrophils and leukocytes at week 120 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Change From Baseline in Hemoglobin at Week 120</measure>
    <time_frame>Baseline, Week 120</time_frame>
    <description>Mean change from baseline in hemoglobin at Week 120 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120</measure>
    <time_frame>Baseline, Week 120</time_frame>
    <description>Mean change from baseline in aspartate aminotransferase and alanine aminotransferase at week 120 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Change From Baseline in Bilirubin at Week 120</measure>
    <time_frame>Baseline, Week 120</time_frame>
    <description>Mean Change From Baseline in Bilirubin at week 120 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. Serious AE (SAE): Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection are reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection were reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. Time to first CTCAE Grade 3 or 4 hematological or liver toxicity was analyzed by treatment group using Kaplan-Meier plots of probability of surviving toxicity-free and point estimates of percentiles. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. 10th, 20th, 25th, 50th and 75th percentiles were estimated from Kaplan-Meier survival curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST), Platelets and Bilirubin. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver Toxicity</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST) and Platelets. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Median Time to Nadir of Absolute Lymphocyte Count</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Median time to nadir of absolute lymphocyte count was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Time to Nadir of Absolute Lymphocyte Count</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Mean time to nadir of absolute lymphocyte count was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal Value</measure>
    <time_frame>Baseline up to Week 120</time_frame>
    <description>Mean time to recovery from nadir of absolute lymphocyte count to normal was reported. Recovery from Nadir is defined as a return to baseline value. Normal absolute lymphocyte count is 1.02 x 10^3 cells/microliter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Population: Mean Change in Corrected QT (QTc) Interval From Baseline</measure>
    <time_frame>Baseline, Week 5, 48, 52 and 96</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Mean change in corrected QT (QTc) interval from baseline was reported.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">867</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cladribine Low/Placebo (LLPP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine High Dose/Placebo (HLPP)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine Low/Low Dose (LLLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine High/Low Dose (HLLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Cladribine Low Dose (PPLL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 3.5 mg/kg/No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine 5.25 mg/kg/No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine Low/Low Dose (LLLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine Low/Placebo (LLPP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine High/Low Dose (HLLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.</description>
    <arm_group_label>Placebo/Cladribine Low Dose (PPLL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.</description>
    <arm_group_label>Cladribine High Dose/Placebo (HLPP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Randomized in Trial 25643 and satisfied one of the following:&#xD;
&#xD;
               -  Completed randomized treatment course and scheduled visits for the full 96 weeks;&#xD;
                  or&#xD;
&#xD;
               -  Did not complete the randomized treatment course in Trial 25643 but elected to&#xD;
                  receive rescue treatment with Rebif®, another beta-interferon, or glatiramer&#xD;
                  acetate and completed scheduled clinic visits for the full 96 weeks; or&#xD;
&#xD;
               -  Did not complete the randomized treatment course in Trial 25643, declined rescue&#xD;
                  with Rebif®, another beta-interferon, or glatiramer acetate and still completed&#xD;
                  scheduled clinic visits for the full 96 weeks; or&#xD;
&#xD;
               -  Did not complete the randomized treatment course in Trial 25643, were not&#xD;
                  eligible for rescue option with Rebif®, and still completed scheduled clinic&#xD;
                  visits for the full 96 weeks&#xD;
&#xD;
          -  Male or female, between 18 and 65 years of age (inclusive, at time of informed consent&#xD;
             for Trial 25643)&#xD;
&#xD;
          -  No medical history or evidence of latent tuberculosis infection (LTBI) or tuberculosis&#xD;
             (TB), as evidenced by TB skin test or chest X-ray&#xD;
&#xD;
          -  All of the following laboratory hematologic parameters evaluated as normal (as define&#xD;
             below, inclusively) within 28 days of first dosing of blinded study medication at&#xD;
             study Day 1:&#xD;
&#xD;
               -  Hemoglobin = 11.6 to 16.2 gram per deciliter (g/dL)&#xD;
&#xD;
               -  Leukocytes (total white blood cell) = 4.1 to 12.3*10^3 per microliter&#xD;
&#xD;
               -  Absolute lymphocyte count (ALC) = 1.02 to 3.36*10^3 per microliter&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) = 2.03 to 8.36*10^3 per microliter&#xD;
&#xD;
               -  Platelet count = 140 to 450*10^3 per microliter&#xD;
&#xD;
          -  Other protocol-defined inclusion/exclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who were not enrolled in Trial 25643&#xD;
&#xD;
          -  Participant has moderate to severe renal impairment&#xD;
&#xD;
          -  Use of mitoxantrone, total lymphoid irradiation, myelosuppressive therapy, campath-1h,&#xD;
             cyclophosphamide, azathioprine, methotrexate or natalizumab at any time during and&#xD;
             since Trial 25643&#xD;
&#xD;
          -  Use of cytokine or anti-cytokine therapy, intravenous immunoglobulin (IVIG) or&#xD;
             plasmapheresis at any time during and since Trial 25643&#xD;
&#xD;
          -  Treatment with oral or systemic corticosteroids or adrenocorticotropic hormone within&#xD;
             28 days before Study Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Diepenbeek</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esneux</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shuman</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burnaby</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beyrouth</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fes</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rabat</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sittard- Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reseach Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monastir</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Morocco</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Serbia</country>
    <country>Switzerland</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=27820</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 13, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <results_first_submitted>September 30, 2013</results_first_submitted>
  <results_first_submitted_qc>September 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2013</results_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 1326 subjects were randomized into CLARITY from study 25643 (NCT00213135), of whom 867 consented to participate in this phase 3b extension Study 27820. 806 subjects were randomized or assigned to treatment and a further 61 subjects were followed for safety only (Supplemental follow-up period [no study treatment] [SAFUP]).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
        </group>
        <group group_id="P2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="P3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="P4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="P6">
          <title>Placebo/No Treatment</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="P7">
          <title>Cladribine 3.5 mg/kg/No Treatment</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="P8">
          <title>Cladribine 5.25 mg/kg/No Treatment</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>96-week Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="186"/>
                <participants group_id="P4" count="186"/>
                <participants group_id="P5" count="244"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="166"/>
                <participants group_id="P4" count="174"/>
                <participants group_id="P5" count="227"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-Week Supplemental Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="143"/>
                <participants group_id="P4" count="151"/>
                <participants group_id="P5" count="198"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="140"/>
                <participants group_id="P4" count="147"/>
                <participants group_id="P5" count="193"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) population included all participants who were randomized in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
        </group>
        <group group_id="B2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="B3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="B4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="B5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="186"/>
            <count group_id="B4" value="186"/>
            <count group_id="B5" value="244"/>
            <count group_id="B6" value="806"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="10.7"/>
                    <measurement group_id="B2" value="40.8" spread="9.6"/>
                    <measurement group_id="B3" value="40.6" spread="10.5"/>
                    <measurement group_id="B4" value="41.4" spread="10.1"/>
                    <measurement group_id="B5" value="41.6" spread="9.6"/>
                    <measurement group_id="B6" value="41.1" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="156"/>
                    <measurement group_id="B6" value="531"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="88"/>
                    <measurement group_id="B6" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity</title>
        <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic Toxicity</title>
          <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocyte toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophil Count Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Transaminase Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AsparateTransaminase Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin Toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120</title>
        <description>Mean change from baseline in absolute lymphocyte count, platelet, neutrophils and leukocytes at week 120 were reported.</description>
        <time_frame>Baseline, Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120</title>
          <description>Mean change from baseline in absolute lymphocyte count, platelet, neutrophils and leukocytes at week 120 were reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocyte Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="142"/>
                    <count group_id="O5" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="0.3" spread="0.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.4"/>
                    <measurement group_id="O4" value="0.0" spread="0.5"/>
                    <measurement group_id="O5" value="-0.6" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="143"/>
                    <count group_id="O5" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="26.2"/>
                    <measurement group_id="O2" value="-11.9" spread="35.3"/>
                    <measurement group_id="O3" value="-20.6" spread="37.9"/>
                    <measurement group_id="O4" value="-9.7" spread="51.2"/>
                    <measurement group_id="O5" value="-34.0" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="136"/>
                    <count group_id="O4" value="144"/>
                    <count group_id="O5" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.5"/>
                    <measurement group_id="O2" value="0.5" spread="1.2"/>
                    <measurement group_id="O3" value="-0.2" spread="1.5"/>
                    <measurement group_id="O4" value="-0.1" spread="1.4"/>
                    <measurement group_id="O5" value="-0.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="142"/>
                    <count group_id="O5" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.3"/>
                    <measurement group_id="O2" value="0.1" spread="1.2"/>
                    <measurement group_id="O3" value="-0.2" spread="1.4"/>
                    <measurement group_id="O4" value="-0.2" spread="1.3"/>
                    <measurement group_id="O5" value="-0.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Change From Baseline in Hemoglobin at Week 120</title>
        <description>Mean change from baseline in hemoglobin at Week 120 was reported.</description>
        <time_frame>Baseline, Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Change From Baseline in Hemoglobin at Week 120</title>
          <description>Mean change from baseline in hemoglobin at Week 120 was reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>grams per deciliter (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.9"/>
                    <measurement group_id="O2" value="0.2" spread="0.7"/>
                    <measurement group_id="O3" value="-0.1" spread="0.9"/>
                    <measurement group_id="O4" value="0.1" spread="0.9"/>
                    <measurement group_id="O5" value="-0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120</title>
        <description>Mean change from baseline in aspartate aminotransferase and alanine aminotransferase at week 120 were reported.</description>
        <time_frame>Baseline, Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120</title>
          <description>Mean change from baseline in aspartate aminotransferase and alanine aminotransferase at week 120 were reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
          <units>Units per litre (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="142"/>
                <count group_id="O5" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aspartate Aminotransferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="142"/>
                    <count group_id="O5" value="184"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="10.6"/>
                    <measurement group_id="O2" value="-1.1" spread="6.4"/>
                    <measurement group_id="O3" value="2.2" spread="7.3"/>
                    <measurement group_id="O4" value="0.7" spread="11.3"/>
                    <measurement group_id="O5" value="0.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Aminotransferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="142"/>
                    <count group_id="O5" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="26.0"/>
                    <measurement group_id="O2" value="-1.0" spread="11.7"/>
                    <measurement group_id="O3" value="4.3" spread="14.3"/>
                    <measurement group_id="O4" value="0.7" spread="17.5"/>
                    <measurement group_id="O5" value="1.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Change From Baseline in Bilirubin at Week 120</title>
        <description>Mean Change From Baseline in Bilirubin at week 120 was reported.</description>
        <time_frame>Baseline, Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Change From Baseline in Bilirubin at Week 120</title>
          <description>Mean Change From Baseline in Bilirubin at week 120 was reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>micromoles per liter (mcmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="137"/>
                <count group_id="O4" value="144"/>
                <count group_id="O5" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.7"/>
                    <measurement group_id="O2" value="0.0" spread="3.5"/>
                    <measurement group_id="O3" value="-0.8" spread="3.7"/>
                    <measurement group_id="O4" value="-0.8" spread="3.3"/>
                    <measurement group_id="O5" value="-0.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. Serious AE (SAE): Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. Serious AE (SAE): Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="149"/>
                    <measurement group_id="O4" value="149"/>
                    <measurement group_id="O5" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</title>
        <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>SAFUP Analysis Set included all participants who were enrolled and had at least one safety assessment, but were not randomized or assigned to treatment because they were not eligible to receive study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/No Treatment</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg/No Treatment</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
          <group group_id="O3">
            <title>Cladribine 5.25 mg/kg/No Treatment</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
        </group_list>
        <measure>
          <title>SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs</title>
          <description>An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. Number of participants with TEAEs included participants with both non-serious TEAEs and serious TEAEs.</description>
          <population>SAFUP Analysis Set included all participants who were enrolled and had at least one safety assessment, but were not randomized or assigned to treatment because they were not eligible to receive study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</title>
        <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection are reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</title>
          <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection are reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="186"/>
                <count group_id="O4" value="186"/>
                <count group_id="O5" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Herpes viral infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infectious disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="92"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</title>
        <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection were reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>SAFUP Analysis Set included all participants who were enrolled and had at least one safety assessment, but were not randomized or assigned to treatment because they were not eligible to receive study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/No Treatment</title>
            <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine 3.5 mg/kg/No Treatment</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
          <group group_id="O3">
            <title>Cladribine 5.25 mg/kg/No Treatment</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
          </group>
        </group_list>
        <measure>
          <title>SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and Malignancies</title>
          <description>Number of participants who developed Herpes viral infection, Viral infectious disorder and Opportunistic infection were reported. Number of participants with infection related adverse events are the number of participants who had at least one adverse event coded to medical dictionary for regulatory activities (MedDRA) preferred terms under infection and infestation system organ class. Malignancy is defined as having at least one adverse event coded to MedDRA preferred terms under the pre-specified grouping Malignant and unspecified tumors.</description>
          <population>SAFUP Analysis Set included all participants who were enrolled and had at least one safety assessment, but were not randomized or assigned to treatment because they were not eligible to receive study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Herpes viral infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Opportunistic infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Viral infectious disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections related adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignancies</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver Toxicity</title>
        <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. Time to first CTCAE Grade 3 or 4 hematological or liver toxicity was analyzed by treatment group using Kaplan-Meier plots of probability of surviving toxicity-free and point estimates of percentiles. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. 10th, 20th, 25th, 50th and 75th percentiles were estimated from Kaplan-Meier survival curve.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number Analyzed&quot;signifies those participants who were evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver Toxicity</title>
          <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events version 3.0 (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. Time to first CTCAE Grade 3 or 4 hematological or liver toxicity was analyzed by treatment group using Kaplan-Meier plots of probability of surviving toxicity-free and point estimates of percentiles. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. 10th, 20th, 25th, 50th and 75th percentiles were estimated from Kaplan-Meier survival curve.</description>
          <population>Safety population included all the randomized participants who had received at least 1dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number Analyzed&quot;signifies those participants who were evaluable for specified category.</population>
          <units>Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="76"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10th percentile: Lymphocytes Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="14" lower_limit="8" upper_limit="34"/>
                    <measurement group_id="O4" value="8" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="O5" value="362" lower_limit="85" upper_limit="378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: Lymphocytes Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="58" lower_limit="34" upper_limit="162"/>
                    <measurement group_id="O4" value="15" lower_limit="12" upper_limit="50"/>
                    <measurement group_id="O5" value="412" lower_limit="379" upper_limit="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: Lymphocytes Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="108" lower_limit="57" upper_limit="379"/>
                    <measurement group_id="O4" value="34" lower_limit="15" upper_limit="57"/>
                    <measurement group_id="O5" value="583" lower_limit="406" upper_limit="NA">Due to higher percentiles not attained, upper limit of 95% Confidence Interval from the Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: Lymphocytes Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="449" lower_limit="361" upper_limit="NA">Due to higher percentiles not attained, upper limit of 95% Confidence Interval from the Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: Lymphocytes Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: ANC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20th percentile: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25th percentile: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50th percentile: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75th percentile: AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Due to small number of events, estimates from Kaplan-Meier survival curves could not be derived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile: Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>20th percentile: Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>25th percentile: Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>50th percentile: Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>75th percentile: Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic Toxicity</title>
        <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST), Platelets and Bilirubin. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number Analyzed signifies those participants who were evaluable for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic Toxicity</title>
          <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE version 3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST), Platelets and Bilirubin. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
          <population>Safety population included all the randomized participants who had received at least 1dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number Analyzed signifies those participants who were evaluable for specified category.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocyte</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="14" upper_limit="85"/>
                    <measurement group_id="O2" value="31.5" lower_limit="26" upper_limit="51"/>
                    <measurement group_id="O3" value="212.0" lower_limit="8" upper_limit="1184"/>
                    <measurement group_id="O4" value="168.0" lower_limit="7" upper_limit="799"/>
                    <measurement group_id="O5" value="111.3" lower_limit="5" upper_limit="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="99.0" lower_limit="99" upper_limit="99"/>
                    <measurement group_id="O3" value="64.0" lower_limit="64" upper_limit="64"/>
                    <measurement group_id="O4" value="57.0" lower_limit="57" upper_limit="57"/>
                    <measurement group_id="O5" value="173.5" lower_limit="22" upper_limit="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="29.0" lower_limit="29" upper_limit="29"/>
                    <measurement group_id="O3" value="30.0" lower_limit="19" upper_limit="295"/>
                    <measurement group_id="O4" value="42.5" lower_limit="19" upper_limit="715"/>
                    <measurement group_id="O5" value="79.0" lower_limit="28" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophil Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0" lower_limit="13" upper_limit="91"/>
                    <measurement group_id="O2" value="57.0" lower_limit="29" upper_limit="85"/>
                    <measurement group_id="O3" value="23.8" lower_limit="8" upper_limit="85"/>
                    <measurement group_id="O4" value="34.0" lower_limit="19" upper_limit="127"/>
                    <measurement group_id="O5" value="37.5" lower_limit="15" upper_limit="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="197.0" lower_limit="197" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Transaminase (ALT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" lower_limit="51" upper_limit="94"/>
                    <measurement group_id="O4" value="73.0" lower_limit="19" upper_limit="127"/>
                    <measurement group_id="O5" value="15.0" lower_limit="1" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Transaminase (AST)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" lower_limit="51" upper_limit="94"/>
                    <measurement group_id="O3" value="84.0" lower_limit="84" upper_limit="84"/>
                    <measurement group_id="O4" value="18.0" lower_limit="18" upper_limit="18"/>
                    <measurement group_id="O5" value="55.0" lower_limit="55" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver Toxicity</title>
        <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST) and Platelets. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver Toxicity</title>
          <description>Hematologic and hepatic toxicity was assessed using Common Terminology Criteria for Adverse Events (CTCAE). Hematologic and hepatic function included absolute lymphocyte count (ALC), hemoglobin level, white blood cell (WBC) count, absolute neutrophil count (ANC), platelets, alanine transaminase (ALT), aspartate transaminase (AST) and bilirubin. According to CTCAE v3.0: Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death. Time to recovery from grade 3 or 4 hematological or liver toxicity were reported: lymphocytes, platelets, neutrophils, white blood cells, hemoglobin, Alanine transaminase (ALT), Aspartate transaminase (AST) and Platelets. Recovery from a Grade 3 or 4 toxicity is defined as a return to a Grade 0 or 1.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="89"/>
                <count group_id="O5" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocyte</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="33.5"/>
                    <measurement group_id="O2" value="34.9" spread="11.7"/>
                    <measurement group_id="O3" value="256.7" spread="239.7"/>
                    <measurement group_id="O4" value="241.8" spread="216.1"/>
                    <measurement group_id="O5" value="160.2" spread="160.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="99.0"/>
                    <measurement group_id="O3" value="64.0"/>
                    <measurement group_id="O4" value="57.0"/>
                    <measurement group_id="O5" value="173.5" spread="214.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="79.3" spread="91.9"/>
                    <measurement group_id="O4" value="132.0" spread="213.9"/>
                    <measurement group_id="O5" value="71.5" spread="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophil Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" spread="39.3"/>
                    <measurement group_id="O2" value="57.0" spread="39.6"/>
                    <measurement group_id="O3" value="35.3" spread="29.9"/>
                    <measurement group_id="O4" value="46.8" spread="35.1"/>
                    <measurement group_id="O5" value="61.0" spread="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="197.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Transaminase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="30.4"/>
                    <measurement group_id="O4" value="73.0" spread="76.4"/>
                    <measurement group_id="O5" value="23.7" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Transaminase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="30.4"/>
                    <measurement group_id="O3" value="84.0"/>
                    <measurement group_id="O4" value="18.0"/>
                    <measurement group_id="O5" value="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Median Time to Nadir of Absolute Lymphocyte Count</title>
        <description>Median time to nadir of absolute lymphocyte count was reported.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Median Time to Nadir of Absolute Lymphocyte Count</title>
          <description>Median time to nadir of absolute lymphocyte count was reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>97.5% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="175"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.0" lower_limit="86" upper_limit="372"/>
                    <measurement group_id="O2" value="93.0" lower_limit="37" upper_limit="252"/>
                    <measurement group_id="O3" value="365.0" lower_limit="246" upper_limit="379"/>
                    <measurement group_id="O4" value="162.0" lower_limit="106" upper_limit="359"/>
                    <measurement group_id="O5" value="380.0" lower_limit="379" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Time to Nadir of Absolute Lymphocyte Count</title>
        <description>Mean time to nadir of absolute lymphocyte count was reported.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Time to Nadir of Absolute Lymphocyte Count</title>
          <description>Mean time to nadir of absolute lymphocyte count was reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="175"/>
                <count group_id="O5" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.0" spread="296.7"/>
                    <measurement group_id="O2" value="193.6" spread="219.1"/>
                    <measurement group_id="O3" value="276.7" spread="191.7"/>
                    <measurement group_id="O4" value="241.1" spread="200.3"/>
                    <measurement group_id="O5" value="362.9" spread="177.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal Value</title>
        <description>Mean time to recovery from nadir of absolute lymphocyte count to normal was reported. Recovery from Nadir is defined as a return to baseline value. Normal absolute lymphocyte count is 1.02 x 10^3 cells/microliter.</description>
        <time_frame>Baseline up to Week 120</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal Value</title>
          <description>Mean time to recovery from nadir of absolute lymphocyte count to normal was reported. Recovery from Nadir is defined as a return to baseline value. Normal absolute lymphocyte count is 1.02 x 10^3 cells/microliter.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="128"/>
                <count group_id="O5" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.0" spread="72.4"/>
                    <measurement group_id="O2" value="72.7" spread="61.3"/>
                    <measurement group_id="O3" value="237.5" spread="214.7"/>
                    <measurement group_id="O4" value="245.3" spread="222.3"/>
                    <measurement group_id="O5" value="187.8" spread="180.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety Population: Mean Change in Corrected QT (QTc) Interval From Baseline</title>
        <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Mean change in corrected QT (QTc) interval from baseline was reported.</description>
        <time_frame>Baseline, Week 5, 48, 52 and 96</time_frame>
        <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cladribine Low/Placebo (LLPP)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
          </group>
          <group group_id="O2">
            <title>Cladribine High Dose/Placebo (HLPP)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O3">
            <title>Cladribine Low/Low Dose (LLLL)</title>
            <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O4">
            <title>Cladribine High/Low Dose (HLLL)</title>
            <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
          <group group_id="O5">
            <title>Placebo/Cladribine Low Dose (PPLL)</title>
            <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Population: Mean Change in Corrected QT (QTc) Interval From Baseline</title>
          <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Mean change in corrected QT (QTc) interval from baseline was reported.</description>
          <population>Safety population included all the randomized participants who had received at least 1 dose of study medication and had follow-up safety data. Here 'Number of participants analyzed' signifies number of participants who were evaluable for this outcome measure and and &quot;Number analyzed&quot; are those who were evaluable at specified category.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="21.6"/>
                    <measurement group_id="O2" value="7.4" spread="21.2"/>
                    <measurement group_id="O3" value="4.5" spread="20.6"/>
                    <measurement group_id="O4" value="4.3" spread="16.2"/>
                    <measurement group_id="O5" value="0.7" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="18.6"/>
                    <measurement group_id="O2" value="7.4" spread="23.6"/>
                    <measurement group_id="O3" value="9.3" spread="19.8"/>
                    <measurement group_id="O4" value="11.3" spread="19.5"/>
                    <measurement group_id="O5" value="7.2" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="17.5"/>
                    <measurement group_id="O2" value="22.3" spread="25.4"/>
                    <measurement group_id="O3" value="8.4" spread="22.8"/>
                    <measurement group_id="O4" value="5.2" spread="18.8"/>
                    <measurement group_id="O5" value="-1.2" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="25.5"/>
                    <measurement group_id="O2" value="-4.5" spread="32.5"/>
                    <measurement group_id="O3" value="-12.5" spread="22.2"/>
                    <measurement group_id="O4" value="1.6" spread="22.7"/>
                    <measurement group_id="O5" value="-6.2" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 120</time_frame>
      <desc>For LLPP, HLPP, LLLL, HLLL and PPLL arms: Safety population included all the randomized participants who had received at least 1dose of study medication and had follow-up safety data. For Placebo/No treatment, Cladribine 3.5 mg/kg/No Treatment and Cladribine 5.25 mg/kg/No Treatment: SAFUP Analysis Set included all participants who were enrolled and had at least one safety assessment, but were not randomized or assigned to treatment because they were not eligible to receive study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cladribine Low/Placebo (LLPP)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in Supplemental follow-up period (SUPF).</description>
        </group>
        <group group_id="E2">
          <title>Cladribine High Dose/Placebo (HLPP)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to placebo (matched to cladribine tablet) during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="E3">
          <title>Cladribine Low/Low Dose (LLLL)</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="E4">
          <title>Cladribine High/Low Dose (HLLL)</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="E5">
          <title>Placebo/Cladribine Low Dose (PPLL)</title>
          <description>Participants who received placebo in previous study 25643 (NCT00213135) and completed the study who were randomized or assigned to cladribine 3.5 mg/kg orally provided as 0.875 mg/kg treatment weeks at Week 1, Week 5, Week 48 and Week 52 resulting in total dose of 3.5 mg/kg during the treatment period of 96 weeks. Participants were followed up for 24 weeks in SUPF.</description>
        </group>
        <group group_id="E6">
          <title>Placebo/No Treatment</title>
          <description>Participants who received placebo matched to cladribine in previous study 25643 (NCT00213135) and were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="E7">
          <title>Cladribine 3.5 mg/kg/No Treatment</title>
          <description>Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
        <group group_id="E8">
          <title>Cladribine 5.25 mg/kg/No Treatment</title>
          <description>Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Biliary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary immunodeficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urethral abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood culture positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pregnancy test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tuberculin test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breast fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Juvenile melanoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neurilemmoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma Stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Venous Stasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="143" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="146" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="192" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anisocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eosinophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eosinophil Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Macrocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Poikilocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Red Blood Cell Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Retinal Tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Aphthous Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infected insect bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Skin bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tooth Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection Site Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection Site Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Red blood cell burr cells present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood Potassium Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood Thyroid Stimulating Hormone Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blood Urine Present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Monocyte Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Red Blood Cell Morphology Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Smear Cervix Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thyroid Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Patellofemoral Pain Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bone Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pancreatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Facial Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Protein Urine Present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Breath Sounds Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ingrowing Nail</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Communication Center</name_or_title>
      <organization>Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@emdgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

